Agammaglobulinemia

Summary

Agammaglobulinemia (MONDO:0015977) is a disease (an umbrella term covering 10 Mondo subtypes) with 6 cohort genes and 14 clinical trials. Top therapeutic interventions include dextrose and human immunoglobulin g.

At a glance

• Prevalence: 1-9 / 1 000 000 (France) [Orphanet-validated]
• Umbrella term: 10 Mondo subtypes
• Cohort genes: 6
• ClinVar variants: 133
• Clinical trials: 14

Clinical features

Epidemiology

Prevalence records

9 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 1 000 000	0.287	France	Validated
Point prevalence	1-9 / 1 000 000	0.134	Spain	Validated
Point prevalence	1-9 / 1 000 000	0.192	Netherlands	Validated
Point prevalence	<1 / 1 000 000	0.045	Turkey	Validated
Point prevalence	<1 / 1 000 000	0.094	United Kingdom	Validated
Point prevalence	1-9 / 1 000 000	0.205	Italy	Validated
Point prevalence	<1 / 1 000 000	0.077	Germany	Validated
Point prevalence	<1 / 1 000 000	0.071	Poland	Validated
Point prevalence	1-9 / 1 000 000	0.13	Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	agammaglobulinemia
Mondo ID	MONDO:0015977
MeSH	D000361
OMIM	601495
Orphanet	183669
DOID	DOID:2583
UMLS	C0001768
MedGen	168
GARD	0020320
MedDRA	10001471
Is cancer (heuristic)	no

Also known as: agammaglobulinemia · antibody Deficiency · Gammaglobulin Deficiency · Immunoglobulin Deficiency

Data availability: 133 ClinVar variants · 3 GenCC gene-disease records.

Disease family

An umbrella term covering 10 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › immune system disorder › inborn error of immunity › B cell deficiency › agammaglobulinemia

Related subtypes (4): immunoglobulin beta deficiency, hyperimmunoglobulin syndrome, selective immunoglobulin deficiency disease, PAX5-related B lymphopenia and autism spectrum disorder

Subtypes (10): congenital agammaglobulinemia, immunodeficiency 61, Good syndrome, isolated agammaglobulinemia, syndromic agammaglobulinemia, activated PI3K-delta syndrome, agammaglobulinemia 9, autosomal recessive, agammaglobulinemia 10, autosomal dominant, agammaglobulinemia, autosomal recessive, due to BOB1 deficiency, agammaglobulinemia 8b, autosomal recessive

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

133 retrieved; paginated sample, class counts are floors:

99 benign, 21 pathogenic, 10 uncertain significance, 2 likely pathogenic, 1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
3392518	NM_003120.3(SPI1):c.[147_155del;157T>G159C>G]		Pathogenic	no assertion criteria provided
3392517	Single allele	AGBL2	Pathogenic	no assertion criteria provided
1335903	NM_003120.3(SPI1):c.363C>A (p.Tyr121Ter)	SPI1	Pathogenic	criteria provided, single submitter
3341167	NM_003120.3(SPI1):c.100G>T (p.Glu34Ter)	SPI1	Pathogenic	no assertion criteria provided
3341168	NM_003120.3(SPI1):c.471del (p.Leu159fs)	SPI1	Pathogenic	no assertion criteria provided
3341179	NM_003120.3(SPI1):c.525C>A (p.Phe175Leu)	SPI1	Pathogenic	no assertion criteria provided
3341190	NM_003120.3(SPI1):c.538C>T (p.Leu180Phe)	SPI1	Pathogenic	no assertion criteria provided
3341200	NM_003120.3(SPI1):c.571T>C (p.Trp191Arg)	SPI1	Pathogenic	no assertion criteria provided
3341201	NM_003120.3(SPI1):c.639G>A (p.Trp213Ter)	SPI1	Pathogenic	no assertion criteria provided
3341202	NM_003120.3(SPI1):c.676C>T (p.Gln226Ter)	SPI1	Pathogenic	no assertion criteria provided
3341203	NM_003120.3(SPI1):c.701del (p.Asn234fs)	SPI1	Pathogenic	no assertion criteria provided
3341204	NM_003120.3(SPI1):c.112del (p.Tyr38fs)	SPI1	Pathogenic	no assertion criteria provided
3341205	NM_003120.3(SPI1):c.733AAG[2] (p.Lys247del)	SPI1	Pathogenic	no assertion criteria provided
3341235	NM_003120.3(SPI1):c.346C>T (p.Arg116Trp)	SPI1	Pathogenic	no assertion criteria provided
3341255	NM_003120.3(SPI1):c.407del (p.Gly136fs)	SPI1	Pathogenic	no assertion criteria provided
3341265	NM_003120.3(SPI1):c.438dup (p.Asp147Ter)	SPI1	Pathogenic	no assertion criteria provided
3341276	NM_003120.3(SPI1):c.441del (p.Asp147fs)	SPI1	Pathogenic	no assertion criteria provided
3392519	NM_003120.3(SPI1):c.536T>C (p.Leu179Pro)	SPI1	Pathogenic	no assertion criteria provided
585156	NM_001080547.2(SPI1):c.325_327delinsAG (p.Gly109fs)	SPI1	Pathogenic	no assertion criteria provided
989449	NM_003120.3(SPI1):c.693_694del (p.Leu232fs)	SPI1	Pathogenic	no assertion criteria provided
989450	NM_003120.3(SPI1):c.328C>T (p.Gln110Ter)	SPI1	Pathogenic	criteria provided, single submitter
801321	NM_003120.3(SPI1):c.722T>G (p.Val241Gly)	SPI1	Likely pathogenic	criteria provided, single submitter
801322	NM_003120.3(SPI1):c.632A>C (p.His211Pro)	SPI1	Likely pathogenic	criteria provided, single submitter
2870679	NM_001330360.2(POLA1):c.3944G>A (p.Arg1315His)	POLA1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2319048	NM_003120.3(SPI1):c.283G>A (p.Val95Ile)	SPI1	Uncertain significance	criteria provided, single submitter
2403927	NM_003120.3(SPI1):c.442G>A (p.Gly148Ser)	SPI1	Uncertain significance	criteria provided, single submitter
2553801	NM_003120.3(SPI1):c.409G>A (p.Glu137Lys)	SPI1	Uncertain significance	criteria provided, single submitter
3169075	NM_003120.3(SPI1):c.293C>T (p.Thr98Ile)	SPI1	Uncertain significance	criteria provided, single submitter
3169079	NM_003120.3(SPI1):c.760G>A (p.Gly254Ser)	SPI1	Uncertain significance	criteria provided, single submitter
3341207	NM_003120.3(SPI1):c.37G>A (p.Val13Ile)	SPI1	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
SLC39A7	Strong	Autosomal recessive	agammaglobulinemia 9, autosomal recessive	3
POU2AF1	Moderate	Autosomal recessive	agammaglobulinemia
TNFSF13	Limited	Autosomal recessive	agammaglobulinemia	2

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SLC39A7	Orphanet:693627	Agammaglobulinemia-skin involvement-failure to thrive syndrome
POU2AF1	Orphanet:186	Primary biliary cholangitis
SPI1	Orphanet:33110	Autosomal non-syndromic agammaglobulinemia
POLA1	Orphanet:163976	X-linked intellectual disability, Van Esch type
POLA1	Orphanet:85453	X-linked reticulate pigmentary disorder

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TNFSF13	HGNC:11928	ENSG00000161955	O75888	Tumor necrosis factor ligand superfamily member 13	gencc
SLC39A7	HGNC:4927	ENSG00000112473	Q92504	Zinc transporter SLC39A7	gencc
POU2AF1	HGNC:9211	ENSG00000110777	Q16633	POU domain class 2-associating factor 1	gencc
SPI1	HGNC:11241	ENSG00000066336	P17947	Transcription factor PU.1	clinvar
AGBL2	HGNC:26296	ENSG00000165923	Q5U5Z8	Cytosolic carboxypeptidase 2	clinvar
POLA1	HGNC:9173	ENSG00000101868	P09884	DNA polymerase alpha catalytic subunit	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TNFSF13	Tumor necrosis factor ligand superfamily member 13	Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA.
SLC39A7	Zinc transporter SLC39A7	Transports Zn(2+) from the endoplasmic reticulum (ER)/Golgi apparatus to the cytosol, playing an essential role in the regulation of cytosolic zinc levels.
POU2AF1	POU domain class 2-associating factor 1	Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2.
SPI1	Transcription factor PU.1	Pioneer transcription factor, which controls hematopoietic cell fate by decompacting stem cell heterochromatin and allowing other transcription factors to enter otherwise inaccessible genomic sites.
AGBL2	Cytosolic carboxypeptidase 2	Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins.
POLA1	DNA polymerase alpha catalytic subunit	Catalytic subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 4 · Druggable fraction: 0.17

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	1	6.1×	0.459
Transcription factor	1	1.4×	0.539
Other/Unknown	4	1.2×	0.539

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TNFSF13	Other/Unknown	no		TNF_dom, Tumour_necrosis_fac-like_dom, TNF_CS
SLC39A7	Other/Unknown	no		ZIP
POU2AF1	Other/Unknown	no		PD-C2-AF1, OCA
SPI1	Other/Unknown	no		Ets_dom, WH-like_DNA-bd_sf, WH_DNA-bd_sf
AGBL2	Protease	yes		Peptidase_M14, Pepdidase_M14_N, Cytosolic_carboxypeptidase
POLA1	Transcription factor	no	2.7.7.102	DNA-dir_DNA_pol_B_exonuc, DNA-dir_DNA_pol_B_multi_dom, DNA-dir_DNA_pol_B

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	2
leukocyte	2
monocyte	2
body of pancreas	1
islet of Langerhans	1
stromal cell of endometrium	1
cardia of stomach	1
epithelium of nasopharynx	1
pylorus	1
left testis	1
right testis	1
right uterine tube	1
calcaneal tendon	1
sural nerve	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TNFSF13	134	ubiquitous	marker	monocyte, leukocyte, granulocyte
SLC39A7	133	ubiquitous	marker	stromal cell of endometrium, islet of Langerhans, body of pancreas
POU2AF1	222	broad	marker	epithelium of nasopharynx, pylorus, cardia of stomach
SPI1	170	broad	marker	granulocyte, monocyte, leukocyte
AGBL2	133	ubiquitous	marker	right uterine tube, left testis, right testis
POLA1	231	ubiquitous	marker	ventricular zone, sural nerve, calcaneal tendon

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SPI1	3,823
POLA1	3,189
SLC39A7	1,679
POU2AF1	1,344
TNFSF13	1,067
AGBL2	513

Intra-cohort edges

A	B	Sources
POU2AF1	SPI1	string_interaction

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SPI1	P17947	35
POLA1	P09884	21
TNFSF13	O75888	1
SLC39A7	Q92504	1
POU2AF1	Q16633	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
AGBL2	Q5U5Z8	72.22

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 28. Enrichment computed across 6 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
DNA replication initiation	1	285.5×	0.019	POLA1
HuR (ELAVL1) binds and stabilizes mRNA	1	253.8×	0.019	TNFSF13
Zinc transporters	1	228.4×	0.019	SLC39A7
Zinc influx into cells by the SLC39 gene family	1	228.4×	0.019	SLC39A7
Processive synthesis on the lagging strand	1	228.4×	0.019	POLA1
Inhibition of replication initiation of damaged DNA by RB1/E2F1	1	163.1×	0.019	POLA1
Telomere C-strand synthesis initiation	1	163.1×	0.019	POLA1
Polymerase switching	1	163.1×	0.019	POLA1
Removal of the Flap Intermediate	1	163.1×	0.019	POLA1
Metal ion SLC transporters	1	120.2×	0.023	SLC39A7
Polymerase switching on the C-strand of the telomere	1	84.6×	0.029	POLA1
TNFs bind their physiological receptors	1	78.8×	0.029	TNFSF13
G1/S-Specific Transcription	1	71.4×	0.030	POLA1
Activation of the pre-replicative complex	1	65.3×	0.030	POLA1
Carboxyterminal post-translational modifications of tubulin	1	47.6×	0.039	AGBL2
R-HSA-425366	1	36.2×	0.048	SLC39A7
Defective pyroptosis	1	31.3×	0.052	POLA1
Transcriptional regulation by RUNX1	1	29.3×	0.052	SPI1
Transcriptional regulation of granulopoiesis	1	25.1×	0.058	SPI1
RUNX1 regulates transcription of genes involved in differentiation of HSCs	1	19.0×	0.072	SPI1
SLC-mediated transmembrane transport	1	11.8×	0.109	SLC39A7
Transport of small molecules	1	5.0×	0.234	SLC39A7
RNA Polymerase II Transcription	1	4.5×	0.247	SPI1
Post-translational protein modification	1	3.8×	0.274	AGBL2
Gene expression (Transcription)	1	3.6×	0.281	SPI1
Generic Transcription Pathway	1	3.0×	0.312	SPI1
Developmental Biology	1	2.9×	0.312	SPI1
Metabolism of proteins	1	2.5×	0.344	AGBL2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
germinal center B cell differentiation	2	561.7×	3e-04	SPI1, POU2AF1
regulation of ferroptosis	1	2808.7×	0.007	SLC39A7
pro-T cell differentiation	1	1404.3×	0.007	SPI1
negative regulation of neutrophil degranulation	1	1404.3×	0.007	SPI1
regulation of myeloid progenitor cell differentiation	1	1404.3×	0.007	SPI1
positive regulation of myeloid dendritic cell chemotaxis	1	1404.3×	0.007	SPI1
myeloid leukocyte differentiation	1	936.2×	0.007	SPI1
lagging strand elongation	1	936.2×	0.007	POLA1
endothelial to hematopoietic transition	1	936.2×	0.007	SPI1
positive regulation of antifungal innate immune response	1	936.2×	0.007	SPI1
follicular B cell differentiation	1	702.2×	0.007	SPI1
leading strand elongation	1	702.2×	0.007	POLA1
skin epidermis development	1	702.2×	0.007	SLC39A7
positive regulation of microglial cell mediated cytotoxicity	1	702.2×	0.007	SPI1
negative regulation of MHC class II biosynthetic process	1	561.7×	0.007	SPI1
anatomical structure regression	1	561.7×	0.007	SPI1
pericyte cell differentiation	1	561.7×	0.007	SPI1
DNA replication, synthesis of primer	1	468.1×	0.007	POLA1
protein side chain deglutamylation	1	468.1×	0.007	AGBL2
regulation of erythrocyte differentiation	1	468.1×	0.007	SPI1
positive regulation of isotype switching to IgA isotypes	1	468.1×	0.007	TNFSF13
apoptotic process involved in blood vessel morphogenesis	1	468.1×	0.007	SPI1
mitotic DNA replication initiation	1	468.1×	0.007	POLA1
immature B cell differentiation	1	401.2×	0.007	SPI1
oncogene-induced cell senescence	1	401.2×	0.007	SPI1
negative regulation of adipose tissue development	1	401.2×	0.007	SPI1
lymphocyte homeostasis	1	312.1×	0.008	TNFSF13
DNA strand elongation involved in DNA replication	1	312.1×	0.008	POLA1
TRAIL-activated apoptotic signaling pathway	1	312.1×	0.008	SPI1
regulation of type I interferon production	1	280.9×	0.008	POLA1

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Human Immunoglobulin G	Phase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 5

Druggability breadth: 4 of 6 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
POLA1	RUCAPARIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
POLA1	3	4
TNFSF13	0	0
SLC39A7	0	0
POU2AF1	0	0
SPI1	0	0
AGBL2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RUCAPARIB	4	POLA1
ADEFOVIR DIPIVOXIL	4	POLA1
RESVERATROL	3	POLA1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
POLA1	73	Binding:64, ADMET:5, Functional:4
AGBL2	3	Binding:3
SLC39A7	2	Binding:1, Functional:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
POLA1	2.7.7.102	DNA primase AEP

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

3 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
RUCAPARIB	4	POLA1
ADEFOVIR DIPIVOXIL	4	POLA1
RESVERATROL	3	POLA1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	POLA1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	1	AGBL2
E	Difficult family or no structure, no drug	4	TNFSF13, SLC39A7, POU2AF1, SPI1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TNFSF13	0	—
SLC39A7	2	—
POU2AF1	0	—
SPI1	0	—
AGBL2	3	—

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	7
PHASE4	3
Not specified	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07135427	PHASE4	RECRUITING	Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
NCT00520494	PHASE4	COMPLETED	Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
NCT05612607	PHASE4	UNKNOWN	Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies
NCT06954441	PHASE3	RECRUITING	V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency
NCT00168012	PHASE3	COMPLETED	Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
NCT00168025	PHASE3	COMPLETED	Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00220766	PHASE3	COMPLETED	Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
NCT00322556	PHASE3	COMPLETED	Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT01581593	PHASE3	COMPLETED	Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
NCT03578341	PHASE3	UNKNOWN	Oral Colostrum and Its Effect on Immune System
NCT00161993	PHASE2	COMPLETED	Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
NCT05584631	PHASE1	RECRUITING	IVIG vs SCIG in CIDP
NCT00661401	Not specified	COMPLETED	Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin
NCT02972281	Not specified	COMPLETED	Systematic Search for Primary Immunodeficiency in Adults With Infections

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXTROSE	4	1
HUMAN IMMUNOGLOBULIN G	4	1
CHEMBL423707	0	1